Novel Drug Target for Chemotherapy-Induced Peripheral Neuropathy

Request Number REQ2342239
Due Date May 17, 2017
Author Seh-Rin Sung
Request for Proposal Details
RFP Title
Novel Drug Target for Chemotherapy-Induced Peripheral Neuropathy
RFP Description

NineSigma, representing Daiichi Sankyo Co., Ltd. (, seeks a novel drug target (molecule/gene) to prevent/treat chemotherapy-induced peripheral neuropathy (CIPN) in an effective manner.


Proposals are also welcome for highly novel drug targets involved in neuropathic pain or neuroprotection.


Daiichi Sankyo (DS) has designated pain therapy as a priority area and aims to contribute to the improvement of future medical treatment by precisely identifying unmet medical needs and focusing their research and development on drugs that satisfy those needs.


DS has decided to issue this open request with the aim of developing innovative new drugs by combining its advanced knowledge and capability for new drug development in the field of pain held by their promising partner organization.



Insight on how peripheral neuropathy provokes pain in CIPN or post-operative neuropathy has been rapidly progressing, and development of innovative new drugs is eagerly anticipated. However, their pathogenic mechanism is highly complicated and there remain problems in developing revolutionary therapies against them.


To meet unmet needs in the medical practice, DS aims to deliver innovative treatment to patients suffering from neuropathic pain especially for CIPN. To proceed with research and development toward this purpose more effectively, it seeks to recruit a partner organization with excellent research and development seeds in the field for collaboration.




Key Success Criteria

Anticipated drug target molecule(s)/gene(s) should meet the following requirements:

  • Involved in disease mechanism of CIPN; Having a different mechanism of action from that of existing drugs or those under clinical development by other pharmaceutical companies/bioventures;
  • The proposer has substance(s) (such as low molecular weight compounds or, antibodies) acting on the proposed drug target and the hypothesis above has been validated;
    • The proposed drug target should have been validated as a drug target in a study at least in vitro and preferably in vivo.
  • Preferably the proposal will include a methodology or platform to obtain substance(s) acting on the drug target. 


Approaches not of interest

The following approaches are not of interest:

  • Proposals for drug efficacy assessment systems only.
  • Target molecule(s) with the same mechanism of action as that of existing drugs or investigational drugs under development
  • Improvement of anti-cancer drugs.



Preferred Collaboration types
Items to be submitted

Anticipated Project Phases or Project Plan

Applicant organizations are required to submit proposals using the attached Response Template.


The scientists in DS will review proposals and select suitable candidates for collaboration. Once candidates are selected, DS will execute confidential disclosure agreements (CDAs) in order to seek further information disclosure and discuss possible research approaches.

Once the best candidates have been determined, DS will execute licensing/joint/contract research agreements with partners.


Items to be Included in the Proposal

Responses will use the Proposal Template which is linked to the “attachments” shown at the bottom of this page and include the following information:


  • Overview of the drug target(s) (such as characteristics, superiority to existing drug targets)
  • Rationale or data indicating validity as a drug target
  • Current research and development stage
  • Future research and development plans
  • Any request concerning the structure of collaboration
  • Related intellectual property
  • Past research achievements


Area of Interest
Request Priority